AN OPEN-LABEL TRIAL OF THE LONG-TERM SAFETY AND TOLERABILITY OF NINTEDANIB PER OS, ON TOP OF STANDARD OF CARE, OVER AT LEAST 3 YEARS, IN CHILDREN AND ADOLESCENTS WITH CLINICALLY SIGNIFICANT FIBROSING INTERSTITIAL LUNG DISEASE

Registry ID

1199-0378

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

BOEHRINGER INGELHEIM (CANADA) LTD LTEE

Start date

2024-08-16

Completion date

2025-08-08

Last update

2021-09-09

Conditions

• LUNG DISEASE

Related clinical trials

• AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH FIBROTIC LUNG DISEASE
• REDUCING RESPIRATORY SYMPTOMS OF PULMONARY IRRADIATION IN INTERSTITIAL LUNG DISEASE (RESPIRE-ILD): A 2X2 FACTORIAL RANDOMIZED PHASE II TRIAL TESTING N-ACETYL CYSTEINE AND DEXAMETHASONE
• PIONEERING PRE- AND POST-OPERATIVE INTEGRATIVE CARE TO IMPROVE THORACIC CANCER QUALITY OF CARE: THE THORACIC PERI-OPERATIVE INTEGRATIVE SURGICAL CARE EVALUATION (POISE) TRIAL - STAGE III
• PULMONARY IMAGING REGISTRY (PIMREGISTRY) FOR INNOVATION IN RESPIRATORY MEDICINE
• IMAGING MEASURES OF RESPIRATORY HEALTH REGISTRY (IMRH)
• A PHASE 2B, MULTICENTER, RANDOMIZED, OPEN-LABEL, CONTROLLED, 3-ARM STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF SHP607 IN PREVENTING CHRONIC LUNG DISEASE THROUGH 12 MONTHS CORRECTED AGE COMPARED TO STANDARD NEONATAL CARE IN EXTREMELY PREMATURE INFANTS.

View on source registry